In this video from the 2014 ASH Annual Meeting, Dr. Röllig discusses the results of the SORAML trial that tested sorafenib in patients with acute myeloid leukemia.
At the 2014 American Society of Hematology Annual Meeting, Christoph Röllig, MD, of University Hospital Dresden, Germany, discusses the results of the SORAML trial that tested sorafenib compared with placebo as add-on to standard induction and consolidation treatment in patients with acute myeloid leukemia (AML) aged 18 to 60 years.
